Form 4: ClearPoint Neuro Director Timothy Richards Granted Over 12,000 Restricted Stock Units

ClearPoint Neuro, Inc. director Timothy T. Richards was granted 12,417 restricted stock units, which will vest based on future performance or time, aligning his interests with shareholders.

Summary

• Timothy T. Richards, a Director of ClearPoint Neuro, Inc. (CLPT), was granted 12,417 Restricted Stock Units (RSUs) on May 22, 2025.
• Each RSU represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock.
• The RSUs were granted at a price of $0 per unit, which is typical for RSU grants as a form of equity compensation.
• Following this transaction, Mr. Richards beneficially owns 12,417 derivative securities in the form of RSUs.
• The RSUs are scheduled to vest on the earlier of (i) the first anniversary of the grant date (May 22, 2026), or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.

Sentiment

Score: 6

Explanation: The grant of Restricted Stock Units to a director is a standard practice that aligns management's interests with shareholders, generally viewed as a neutral to slightly positive event for corporate governance and long-term alignment, with minimal immediate impact on company operations or financials.

Positives

• The grant of Restricted Stock Units to Director Timothy T. Richards aligns his long-term interests with those of ClearPoint Neuro, Inc. shareholders, as the value of the units is tied to the company's stock performance.
• This RSU grant serves as a form of equity compensation, incentivizing the director to contribute to the company's growth and success.

Negatives

• The vesting of these 12,417 Restricted Stock Units will result in a minor dilution of existing shareholder equity when they convert into common stock.

Future Outlook

The 12,417 Restricted Stock Units granted to Director Timothy T. Richards are scheduled to vest on the earlier of May 22, 2026, or the day immediately preceding the Company's 2026 annual meeting of stockholders, indicating a future conversion to common stock.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, common across all industries for publicly traded companies. It reflects standard corporate governance practices where directors receive equity as part of their compensation package to align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as a form of director compensation is a common practice across publicly traded companies, including those in the medical device and neuro-navigation sectors, such as Medtronic (MDT) or Stryker (SYK), which frequently use equity awards to incentivize executives and directors.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is also a standard approach for time-based equity awards, ensuring continued service and alignment.
• The grant price of $0 is typical for RSU grants, as they represent a right to receive shares, not an option to purchase them at a set price.

Corporate Governance

Related Party Transactions

• The transaction involves a grant of equity compensation from ClearPoint Neuro, Inc. to its director, Timothy T. Richards, which is a standard related party transaction disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of RSUs, but also improved alignment of director's interests with shareholder value.
• Employees: No direct impact on general employees mentioned.

Next Steps

• Vesting of the 12,417 Restricted Stock Units on the earlier of May 22, 2026, or the day immediately preceding ClearPoint Neuro, Inc.'s 2026 annual meeting of stockholders.
• Conversion of vested Restricted Stock Units into ClearPoint Neuro, Inc. common stock.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Restricted Stock Units, RSU, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership, Timothy Richards